Loading...
•
Jun 30
Abeona Therapeutics Q2 2025 Earnings Report
Abeona Therapeutics reported strong earnings in Q2 2025 driven by the PRV sale and the FDA approval of ZEVASKYN.
Key Takeaways
Abeona posted significant net income in Q2 2025, primarily from the $155M PRV sale, alongside FDA approval and launch preparation for ZEVASKYN.
Net income surged to $108.8M due to the PRV sale
FDA approved ZEVASKYN in April 2025, marking a major milestone
Company expects commercial treatment of first ZEVASKYN patient in Q3 2025
Cash position of $225.9M expected to fund operations for over two years
Abeona Therapeutics
Abeona Therapeutics
Abeona Therapeutics Revenue by Segment
Revenue by Segment
License and other Revenue
CapyFin.com Forward Guidance
Abeona expects initial ZEVASKYN treatments to begin in Q3 2025 and projects profitability in 1H 2026, supported by strong patient demand and payer coverage.
Positive Outlook
- First commercial treatment of ZEVASKYN expected in Q3 2025
- Multiple national and regional payers have approved ZEVASKYN
- Strong cash reserves support operations for over two years
- Favorable coverage policy published by United Healthcare
- PRV sale provided $155M in non-dilutive funding
Challenges Ahead
- High SG&A expenses due to commercial launch preparations
- R&D expenses remain elevated despite reclassifications
- Operating income remains negative
- ZEVASKYN revenue not yet realized
- Dependence on successful commercialization for profitability